BRKR vs TMO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BRKR and TMO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BRKR and TMO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.

Full BRKR guide

Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.

Full TMO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BRKR drivers: High-end instruments moat; Adjacent growth vectors.
• TMO drivers: Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. For TMO, the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BRKR if you believe its drivers more; TMO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BRKR and TMO guides.

BRKR. Bruker beat EPS estimates in Q1 2026 (~$0.31 versus ~$0.23) and again in Q2 (~$0.49 versus ~$0.38), even as GAAP results stayed negative. The rally of the past year has lifted the forward multiple to roughly 23x, higher than the 15x to 16x it carried in mid-2026, which leaves less cushion if the expected fourth-quarter rebound in research and semiconductor demand comes in light. The average analyst target is about $63.83 from 12 analysts, though JPMorgan's October downgrade set $60.

TMO. Thermo Fisher's multiple has expanded sharply since mid-2026 as organic growth re-accelerated: the stock trades at roughly 25 times forward earnings and ~37 times trailing GAAP earnings, which include heavy acquisition amortization. Analysts expect 2026 adjusted EPS of ~$25.14 on ~$47.9 billion of revenue, and ~$27.58 on ~$50.4 billion in 2027, both roughly 10% growth. The October 21 third-quarter report will test whether the second quarter's 5% organic growth holds; free cash flow of roughly $6.3 billion in 2025 still gives the company flexibility for repurchases, dividends and acquisitions.

Headline figures (approximate, October 2026): BRKR shows revenue (ttm) ~$3.5B; Q2 2026 revenue ~$838.5M, up ~5.2% YoY, q2 2026 non-gaap eps ~$0.49 vs ~$0.38 consensus, margins Gross ~48.5%, operating ~9.9%; GAAP net margin ~-2% after restructuring and acquisition charges, fy2026 consensus Revenue ~$3.56B, non-GAAP EPS ~$2.12 (prior guidance ~$2.10 to $2.15); TMO shows revenue (ttm) ~$46.3 billion; full year 2025 ~$44.6 billion, q2 2026 revenue ~$11.99 billion, up 10% reported and 5% organic, q2 2026 adjusted eps ~$6.03 (+13%) vs ~$5.71 expected, margins (ttm) Gross ~41%, GAAP operating ~19%, net ~15%.

BRKR and TMO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BRKR and TMO exposure against your real portfolio. It is not an investment adviser.